With the conclusion of another ASCO, we were presented with exciting new breakthrough data of Antibody Drug Conjugates in breast cancer. Enhertu (trastuzumab deruxtecan) demonstrated significant benefit in the treatment of a new subtype of breast cancer, HR+/ /HER2-low.
As ASCO concludes for another year, here at Deallus we were excited to see significant data announcements by Chinese innovators, unveiling enormous potential from China-originated innovation to address unmet needs within the oncology space.
China is never a new word in ASCO. China-originated innovation made its ASCO debut in 2011, and since then we have been seeing more Chinese pharma bringing exciting clinical progress in the oncology space. This year, there will be 19 oral presentations and more than 70 posters from Chinese pharma, with the keyword 'China’ hit a record high of nearly 350 times in the ASCO Agenda.